

# Human TRAIL Monoclonal Antibody

Catalog No.: YR0110

## Basic Information

### Molecular Weight

150 kDa

### Endotoxin

<1EU/mg (<0.001EU/μg) Determined by LAL gel clotting assay

### Sterility

0.2 μm filtration

### Aggregation

<5% Determined by SECP

### Purity

>95% Determined by SDS-PAGE

## Background

Drozitumab is a human monoclonal antibody in development for the treatment of cancers. It targets Tumour Necrosis Factor Related Apoptosis-inducing Ligand (TRAIL), whose receptors are found on the surface of many types of malignant cells. Although drozitumab was studied in phase II trials for treating chondrosarcoma, colorectal cancer, non-Hodgkin lymphoma, and non-small cell lung cancer, development has been halted due to lack of clinical response.

## Reported Applications

ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways

## Immunogen Information

### Clone

Drozitumab Biosimilar

### Isotype

Human IgG1 kappa

### Immunogen

Human TRAIL

### Recommended Isotype Control(s)

In Vivo Grade Recombinant Human IgG1 Kappa Isotype Control Antibody

### Recommended Dilution Buffer

1×PBS pH 7.0

## Contact

☎ | 400-999-6126

✉ | [cn.market@abclonal.com.cn](mailto:cn.market@abclonal.com.cn)

🌐 | [www.abclonal.com.cn](http://www.abclonal.com.cn)

## Product Information

### Production

Purified from cell culture supernatant in an animal-free facility

### Purification

Protein A or G purification

### Storage

2 - 8°C for up to 4 weeks and -80°C for long term storage (Avoid repeated freezing and thawing)